SOX方案联合甲磺酸阿帕替尼治疗晚期不可手术切除胃癌患者的临床疗效评价

目的 观察SOX方案联合甲磺酸阿帕替尼治疗晚期不可手术切除胃癌患者的临床治疗效果。方法 将2017年8月—2018年11月在我院诊治的58例胃癌患者按照就诊顺序随机分为对照组和观察组，对照组30例，观察组28例。对照组给予SOX方案（替吉奥+奥沙利铂）治疗，观察组在此基础上联合甲磺酸阿帕替尼治疗。观察并比较两组患者的近期治疗效果、无进展生存期、总生存期、生活质量及不良反应。结果 对照组患者总有效率为33.33%，疾病临床控制率为73.33%；观察组总有效率为46.43%，疾病临床控制率为85.72%。两组总有效率、疾病临床控制率相比较，差异均有统计学意义（P<0.05）。对照组中位无进展生存时间为6.3个月，中位总生存时间为8.7个月；观察组中位无进展生存时间为8.1个月，中位总生存时间为13.9个月。两组累积无进展生存率、累积生存率相比较，差异均有统计学意义（P<0.05）。两组患者总体健康状况均有好转，躯体功能、认知功能、角色功能、疲倦、疼痛、恶心呕吐评分与治疗前相比较，差异均有统计学意义（P<0.05）。观察组角色功能、食欲丧失、总体健康状况评分与对照组比较，差异均有统计学意义（P<0.05）。两组均未发生严重不良反应。结论 SOX方案联合甲磺酸阿帕替尼治疗晚期不可手术切除胃癌患者具有良好的临床疗效，未见严重不良反应发生，临床可推广使用。

Evaluation of clinical efficacy of SOX regimen combined with apatinib mesylate in the treatment of patients with advanced inoperable gastric cancer

Objective To investigate the clinical effects of SOX program combined with apatinib mesylate in the treatment of patients with advanced inoperable gastric cancer.Methods A total of 58 patients with gastric cancer diagnosed and treated in our hospital between August 2017 and November 2018 were randomly divided into a control group and an observation group according to the order of visits. The control group was treated with S-1 and oxaliplatin, and the observation group was added with apatinib mesylate on the basis of control group. Observe and compare the short-term efficacy, the progression-free survival and overall survival, the quality of life of the patients, as well as the adverse reactions after treatment between the two groups.Results The overall response rate of patients in the control group was 33.33%, and the clinical disease control rate was 73.33%; the overall response rate of the observation group was 46.43%, and the clinical disease control rate was 85.72%. There were statistical differences between the two groups in the overall response rate and clinical disease control rate (P<0.05). The median progression-free survival time was 6.3 months in the control group, and was 8.1 months in the observation group. The median overall survival time was 8.7 months in the control group, and was 13.9 months in the observation group. There were statistical differences between the two groups in the cumulative progression-free survival rate and cumulative survival rate (P<0.05). Patients in both groups had their overall health status improved. The scores of physical function, cognitive function, role function, fatigue, pain, nausea and vomiting after treatment were statistically different from those before treatment in both groups (P<0.05). The scores of the role function, loss of appetite, and overall health of the observation group were statistically different from those of the control group (P<0.05). No serious adverse reactions occurred in the two groups.Conclusion SOX program combined with apatinib mesylate has a good clinical effect in the treatment of patients with advanced inoperable gastric cancer, with no serious adverse reactions, and can be used clinically.